JLE

Innovations & Thérapeutiques en Oncologie

MENU

Approches thérapeutiques actuelles et futures pour les cancers des voies aérodigestives supérieures (HPV+ et HPV-) Volume 5, numéro 2, Mars-Avril 2019

  • [1] Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
  • [2] Kolokythas A. Long-term surgical complications in the oral cancer patient: a comprehensive review. Part II. J Oral Maxillofac Res. 2010;1:e2.
  • [3] Gillison M.L., Koch W.M., Capone R.B. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709-720.
  • [4] Mork J., Lie A.K., Glattre E. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344:1125-1131.
  • [5] D'Souza G., Agrawal Y., Halpern J., Bodison S., Gillison M.L. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis. 2009;199:1263-1269.
  • [6] Gillison M.L. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31:744-754.
  • [7] Fakhry C., Westra W.H., Li S. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261-269.
  • [8] Mirghani H., Amen F., Blanchard P. Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. Int J Cancer. 2015;136:1494-1503.
  • [9] Schiffman M., Castle P.E. The promise of global cervical-cancer prevention. N Engl J Med. 2005;353:2101-2104.
  • [10] Leemans C.R., Snijders P.J.F., Brakenhoff R.H. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18:269-282.
  • [11] Scopus. Scopus database. http://www.scopus.com.
  • [12] Wang C., Dickie J., Sutavani R.V., Pointer C., Thomas G.J., Savelyeva N. Targeting head and neck cancer by vaccination. Front Immunol. 2018;9:830.
  • [13] Macedo R., Rochefort J., Guillot-Delost M. Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles. OncoImmunology. 2016;5:e1164363.
  • [14] Galloway D.A., McDougall J.K. The oncogenic potential of herpes simplex viruses: evidence for a ’hit-and-run’ mechanism. Nature. 1983;302:21-24.
  • [15] Suzich J.A., Ghim S.J., Palmer-Hill F.J. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92:11553-11557.
  • [16] Chaturvedi A.K., Graubard B.I., Broutian T. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2018;36:262-267.
  • [17] Herrero R., Quint W., Hildesheim A. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013;8:e68329.
  • [18] Herrero R., Gonzalez P., Markowitz L.E. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015;16:e206-e216.
  • [19] Bonner J.A., Harari P.M., Giralt J. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
  • [20] Rosenthal D.I., Harari P.M., Giralt J. Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase III registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab. J Clin Oncol. 2016;34:1300-1308.
  • [21] Gillison M.L., Trotti A.M., Harris J. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393:40-50.
  • [22] Mehanna H., Robinson M., Hartley A. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393:51-60.
  • [23] Marur S., Li S., Cmelak A.J. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx – ECOG-ACRIN cancer research group. J Clin Oncol. 2017;35:490-497.
  • [24] Chen A.M., Felix C., Wang P.C. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 2017;18:803-811.
  • [25] O'Sullivan B., Huang S.H., Siu L.L. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013;31:543-550.
  • [26] Ferris R.L., Blumenschein G. Jr., Fayette J. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-1867.
  • [27] Nutting C.M., Morden J.P., Harrington K.J. Parotid-sparing intensity modulated conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12:127-136. versus
  • [28] Petkar I., Bhide S., Newbold K., Harrington K., Nutting C. Dysphagia-optimised intensity-modulated radiotherapy techniques in pharyngeal cancers: is anyone going to swallow it? Clin Oncol. 2017;29:e110-e118.
  • [29] Moon D.H., Moon S.H., Wang K. Incidence of, and risk factors for, mandibular osteoradionecrosis in patients with oral cavity and oropharynx cancers. Oral Oncol. 2017;72:98-103.
  • [30] Cozzi L., Fogliata A., Lomax A., Bolsi A. A treatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours. Radiother Oncol. 2001;61:287-297.
  • [31] Kandula S., Zhu X., Garden A.S. Spot-scanning beam proton therapy intensity-modulated radiation therapy for ipsilateral head and neck malignancies: a treatment planning comparison. Med Dosim. 2013;38:390-394. versus
  • [32] Lomax A.J., Goitein M., Adams J. Intensity modulation in radiotherapy: photons protons in the paranasal sinus. Radiother Oncol. 2003;66:11-18. versus
  • [33] Taheri-Kadkhoda Z., Björk-Eriksson T., Nill S. Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protons. Radiat Oncol. 2008;3:4.
  • [34] Steneker M., Lomax A., Schneider U. Intensity modulated photon and proton therapy for the treatment of head and neck tumors. Radiother Oncol. 2006;80:263-267.
  • [35] Stromberger C., Cozzi L., Budach V. Unilateral and bilateral neck SIB for head and neck cancer patients: intensity-modulated proton therapy, tomotherapy, and RapidArc. Strahlenther Onkol. 2016;192:232-239.
  • [36] Apinorasethkul O., Kirk M., Teo K., Swisher-McClure S., Lukens J.N., Lin A. Pencil beam scanning proton therapy rotational arc radiation therapy: a treatment planning comparison for postoperative oropharyngeal cancer. Med Dosim. 2017;42:7-11. versus
  • [37] Koninklijke Nederlandse Akademie van Wetenschappen. Evaluation of new technology in health care: in need of guidance for relevant evidence. 2014.
  • [38] Langendijk J.A., Boersma L.J., Rasch C.R.N. Clinical trial strategies to compare protons with photons. Semin Radiat Oncol. 2018;28:79-87.
  • [39] Ramaekers B.L.T., Grutters J.P.C., Pijls-Johannesma M., Lambin P., Joore M.A., Langendijk J.A. Protons in head-and-neck cancer: bridging the gap of evidence. Int J Radiat Oncol Biol Phys. 2013;85:1282-1288.
  • [40] Rwigema J-CM, Langendijk J.A., Paul van der Laan H., Lukens J.N., Swisher-McClure S.D., Lin A. A model-based approach to predict short-term toxicity benefits with proton therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2019.
  • [41] Slater J.D., Yonemoto L.T., Mantik D.W. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Radiat Oncol Biol Phys. 2005;62:494-500.
  • [42] Frank S.J., Cox J.D., Gillin M. Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice. Int J Radiat Oncol Biol Phys. 2014;89:846-853.
  • [43] Gunn G.B., Blanchard P., Garden A.S. Clinical outcomes and patterns of disease recurrence after intensity modulated proton therapy for oropharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys. 2016;95:360-367.
  • [44] Russo A.L., Adams J.A., Weyman E.A. Long-term outcomes after proton beam therapy for sinonasal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2016;95:368-376.
  • [45] Beddok A., Feuvret L., Noel G. Efficacy and toxicity of proton with photon radiation for locally advanced nasopharyngeal carcinoma. Acta Oncol. 20191-3.
  • [46] Sio T.T., Lin H.-K., Shi Q. Intensity modulated proton therapy intensity modulated photon radiation therapy for oropharyngeal cancer: first comparative results of patient-reported outcomes. Int J Radiat Oncol Biol Phys. 2016;95:1107-1114. versus
  • [47] Beitler J.J., Chera B.S. Protons for oropharyngeal cancer have not yet justified their promise. Int J Radiat Oncol Biol Phys. 2016;95:1115-1116.
  • [48] Romesser P.B., Cahlon O., Scher E.D. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol Biol Phys. 2016;95:386-395.
  • [49] McDonald M.W., Zolali-Meybodi O., Lehnert S.J. Reirradiation of recurrent and second primary head and neck cancer with proton therapy. Int J Radiat Oncol Biol Phys. 2016;96:808-819.
  • [50] Hayashi Y., Nakamura T., Mitsudo K. Re-irradiation using proton beam therapy combined with weekly intra-arterial chemotherapy for recurrent oral cancer. Asia Pac J Clin Oncol. 2017;13:e394-401.
  • [51] Vermorken J.B., Mesia R., Rivera F. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-1127.
  • [52] Binder-Foucard F, Belot A, Delafosse P, Remontet L, Woronoff A, Bossard N. Estimation nationale incidence mortalité par cancer France 1980-2012 Partie 1 V2. 2018. https://www.e-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers/Donnees-globales.
  • [53] Guigay J., Fayette J., Dillies A.F. Cetuximab, docetaxel and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol. 2015;26:1941-1947.
  • [54] Burtness B, Harrington KJ, Greil R, et al. KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). OncologyPRO. 2018. https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/KEYNOTE-048-Phase-3-study-of-first-line-pembrolizumab-P-for-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-R-M-HNSCC.
  • [55] Haddad R, Argiris A. Study of nivolumab in combination with ipilimumab compared to the standard of care (Extreme study regimen) as first line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck – full text view. ClinicalTrials.gov. 2016. https://clinicaltrials.gov/ct2/show/NCT02741570.
  • [56] Ferris R.L., Even C., Haddad R. Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Eagle. J Immunother Cancer. 2015;3:P150. versusS2
  • [57] Cohen E.E.W., Soulières D., Le Tourneau C. KEYNOTE 040 (III): pembrolizumab methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet. 2019;393:156-167. versus
  • [58] Pfister D, Spencer S, Adelstein D, et al. Head and neck cancers NCCN version 1. 2019. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
  • [59] Machiels J.-P., Haddad R.I., Fayette J. Afatinib methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:583-594. versus
  • [60] Zandberg D.P., Algazi A.P., Jimeno A. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142-152.
  • [61] Siu L.L., Even C., Mesía R. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1 – low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial. JAMA Oncol. 2019;5:195.
  • [62] Newhauser W.D., Zhang R. The physics of proton therapy. Phys Med Biol. 2015;60:R155-209.